WO2003027150A1 - Anticorps et son utilisation - Google Patents

Anticorps et son utilisation Download PDF

Info

Publication number
WO2003027150A1
WO2003027150A1 PCT/JP2002/009840 JP0209840W WO03027150A1 WO 2003027150 A1 WO2003027150 A1 WO 2003027150A1 JP 0209840 W JP0209840 W JP 0209840W WO 03027150 A1 WO03027150 A1 WO 03027150A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
galp
derivative
quantifying
specifically
Prior art date
Application number
PCT/JP2002/009840
Other languages
English (en)
French (fr)
Inventor
Hirokazu Matsumoto
Yasuko Horikoshi
Chieko Kitada
Tetsuya Ohtaki
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to CA002461471A priority Critical patent/CA2461471A1/en
Priority to EP02772904A priority patent/EP1437367A4/en
Priority to US10/490,917 priority patent/US7173112B2/en
Publication of WO2003027150A1 publication Critical patent/WO2003027150A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
PCT/JP2002/009840 2001-09-26 2002-09-25 Anticorps et son utilisation WO2003027150A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002461471A CA2461471A1 (en) 2001-09-26 2002-09-25 Antibody and use thereof
EP02772904A EP1437367A4 (en) 2001-09-26 2002-09-25 ANTIBODIES AND ITS USE
US10/490,917 US7173112B2 (en) 2001-09-26 2002-09-25 Antibody to GALP and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001294528 2001-09-26
JP2001-294528 2001-09-26

Publications (1)

Publication Number Publication Date
WO2003027150A1 true WO2003027150A1 (fr) 2003-04-03

Family

ID=19116111

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009840 WO2003027150A1 (fr) 2001-09-26 2002-09-25 Anticorps et son utilisation

Country Status (5)

Country Link
US (1) US7173112B2 (ja)
EP (1) EP1437367A4 (ja)
JP (1) JP2009215306A (ja)
CA (1) CA2461471A1 (ja)
WO (1) WO2003027150A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0722105D0 (en) 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048920A1 (fr) 1998-03-25 1999-09-30 Takeda Chemical Industries, Ltd. Nouveaux peptides a activite physiologique et leur utilisation
JP2000157273A (ja) 1998-03-25 2000-06-13 Takeda Chem Ind Ltd 新規生理活性ペプチドおよびその用途
JP2000197483A (ja) * 1998-10-30 2000-07-18 Eijiin Kenkyusho:Kk ＲｅｃＱＤＮＡヘリカ―ゼファミリ―遺伝子の変異に起因する疾患の検査方法
JP2000270871A (ja) * 1999-03-24 2000-10-03 Takeda Chem Ind Ltd 新規生理活性ペプチドの製造法
WO2001027273A1 (en) * 1999-10-12 2001-04-19 Lexicon Genetics Incorporated Human galanin family proteins and polynucleotides encoding the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077166A1 (fr) * 2000-04-11 2001-10-18 Takeda Chemical Industries, Ltd. Nouveaux peptides a activite physiologique et leur utilisation
EP1360964A4 (en) * 2001-01-19 2004-03-31 Takeda Chemical Industries Ltd USE OF A GALANINE-LIKE PEPTID

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048920A1 (fr) 1998-03-25 1999-09-30 Takeda Chemical Industries, Ltd. Nouveaux peptides a activite physiologique et leur utilisation
JP2000157273A (ja) 1998-03-25 2000-06-13 Takeda Chem Ind Ltd 新規生理活性ペプチドおよびその用途
JP2000197483A (ja) * 1998-10-30 2000-07-18 Eijiin Kenkyusho:Kk ＲｅｃＱＤＮＡヘリカ―ゼファミリ―遺伝子の変異に起因する疾患の検査方法
JP2000270871A (ja) * 1999-03-24 2000-10-03 Takeda Chem Ind Ltd 新規生理活性ペプチドの製造法
WO2001027273A1 (en) * 1999-10-12 2001-04-19 Lexicon Genetics Incorporated Human galanin family proteins and polynucleotides encoding the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. BIOL. CHEM., vol. 274, 1999, pages 37041
See also references of EP1437367A4 *
TAKATSU Y. ET AL.: "Distribution of galanin-like peptide in the rat brain", ENDOCRINOLOGY, vol. 142, no. 4, 2001, pages 1626 - 1634, XP002961003 *

Also Published As

Publication number Publication date
JP2009215306A (ja) 2009-09-24
US7173112B2 (en) 2007-02-06
EP1437367A1 (en) 2004-07-14
US20040214230A1 (en) 2004-10-28
EP1437367A4 (en) 2005-01-26
CA2461471A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
IL163066A (en) Ligands for the zcytor17 receptor
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
HK1142272A1 (en) Specific binding proteins and uses thereof
NZ597692A (en) Anti-IGF antibodies
WO2005087811A3 (en) Estrogen receptors and methods of use
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
EP2172486A3 (en) Monoclonal antibody against a prion protein and its use for the detection of prions
EP1625163B8 (en) Method of detecting probnp with a monoclonal antibody binding to the amino acids 38-43
NZ547629A (en) Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
WO2003027149A1 (fr) Anticorps et utilisation de ce dernier
EP1066328A4 (en) CHIMERAL PROTEIN, WHICH CONTAINS AN INTRAMOLECULAR CHAPERON-LIKE SEQUENCE AND THEIR APPLICATION FOR INSULIN PRODUCTION
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
WO2003027150A1 (fr) Anticorps et son utilisation
WO2004039842A3 (en) Humanized tissue factor antibodies
CA2597545A1 (en) Antibody for assay of adamts13 activity and method for assaying the activity
WO2006038101A3 (en) Novel cancer associated antibodies and antigens and their use in cancer diagnosis
IL168793A (en) Streptococcus uberis adhesion molecule
EP1455186A4 (en) SCREENING METHOD
NZ612769A (en) Sp35 antibodies and uses thereof
NZ606260A (en) Novel polypeptides involved in immune response
TH87431B (th) แอนติบอดีชนิดแอนติ-il-12, เอพิโทป, สารผสม, วิธี และการใช้

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2461471

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10490917

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002772904

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002772904

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP